ABCC8 p.Arg1379Ser
Predicted by SNAP2: | A: D (91%), C: D (91%), D: D (95%), E: D (95%), F: D (95%), G: D (95%), H: D (91%), I: D (95%), K: D (91%), L: D (95%), M: D (91%), N: D (95%), P: D (95%), Q: D (91%), S: D (91%), T: D (95%), V: D (95%), W: D (95%), Y: D (95%), |
Predicted by PROVEAN: | A: D, C: D, D: D, E: D, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: D, S: D, T: D, V: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Molecular genetic testing of patients with monogen... Mol Genet Metab. 2015 Mar;114(3):451-8. doi: 10.1016/j.ymgme.2014.12.304. Epub 2014 Dec 20. Bennett JT, Vasta V, Zhang M, Narayanan J, Gerrits P, Hahn SH
Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism.
Mol Genet Metab. 2015 Mar;114(3):451-8. doi: 10.1016/j.ymgme.2014.12.304. Epub 2014 Dec 20., [PMID:25555642]
Abstract [show]
Genetic sequencing has become a critical part of the diagnosis of certain forms of pancreatic beta cell dysfunction. Despite great advances in the speed and cost of DNA sequencing, determining the pathogenicity of variants remains a challenge, and requires sharing of sequence and phenotypic data between laboratories. We reviewed all diabetes and hyperinsulinism-associated molecular testing done at the Seattle Children's Molecular Genetics Laboratory from 2009 to 2013. 331 probands were referred to us for molecular genetic sequencing for Neonatal Diabetes (NDM), Maturity-Onset Diabetes of the Young (MODY), or Congenital Hyperinsulinism (CHI) during this period. Reportable variants were identified in 115 (35%) patients with 91 variants in one of 6 genes: HNF1A, GCK, HNF4A, ABCC8, KCNJ11, or INS. In addition to identifying 23 novel variants, we identified unusual mechanisms of inheritance, including mosaic and digenic MODY presentations. Re-analysis of all reported variants using more recently available databases led to a change in variant interpretation from the original report in 30% of cases. These results represent a resource for molecular testing of monogenic forms of diabetes and hyperinsulinism, providing a mutation spectrum for these disorders in a large North American cohort. In addition, they highlight the importance of periodic review of molecular testing results.
Comments [show]
None has been submitted yet.
No. Sentence Comment
121 "Hypoglycemia"* - 1 PATH - - [15] c.4135CNA p.R1379S NDM rs137852673 1 PATH - PATH ClinVar c.4307GNA p.R1436Q n.p. rs387906407 2 PATH PATH PATH [43] c.4543ANG p.T1515A CHI - 1 LP - - This report KCNJ11 c.137ANG p.H46R NDM - 1 PATH - - [44] c.143ANT p.N48I NDM - 2 PATH - - [25] c.497GNA p.C166Y NDM rs80356618 1 PATH - PATH [45] c.601CNT p.R201C NDM rs80356625 1 PATH - PATH [17] c.602GNA p.R201H NDM rs80356624 1 PATH VUS - [45] c.616CNT p.R206C CHI - 1 LP - - This report c.637GNA p.A213T CHI - 1 PATH - - [46] c.685GNA p.E229K NDM - 1 PATH - - [30] c.691GNC/c.970GNA p.V231L/p.G324R NDM -/- 1/1 VUS/VUS -/- -/- This report/this report INS c.-331delC p.?
X
ABCC8 p.Arg1379Ser 25555642:121:46
status: NEW